Biosimilars and non-innovator biotherapeutics in India: An overview of the current situation

Biologicals

Volumn 39, Issue 5, 2011, Pages 321-324

  Malhotra, Hemant ^a  

^a SMS MEDICAL COLLEGE   (India)

Author keywords

Biosimilar products; Copy products; Developing country; India; Non innovator products

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BEVACIZUMAB; BIOLOGICAL PRODUCT; CHORIONIC GONADOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETANERCEPT; FOLLITROPIN; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; HUMAN MENOPAUSAL GONADOTROPIN; INFLIXIMAB; INTERLEUKIN 2; LUTEINIZING HORMONE; PALIVIZUMAB; PARATHYROID HORMONE; PEGINTERFERON ALPHA; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; TRASTUZUMAB;

ARTICLE; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; EUROPE; FINANCIAL MANAGEMENT; GOOD MANUFACTURING PRACTICE; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HUMAN; INDIA; PATENT; POVERTY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RISK BENEFIT ANALYSIS; WORLD HEALTH ORGANIZATION;

COSTS AND COST ANALYSIS; DRUG INDUSTRY; GUIDELINES AS TOPIC; HUMANS; INDIA; LEGISLATION, DRUG; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS;

EID: 80053568200     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.06.018     Document Type: Article

References (11)

1. Guidelines on evaluation of similar biotherapeutic products (SBPs): http://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/guidelines_biotherapeutic_products_final_hk_ik_12_june.pdf.
2. European Medicines Agency (EMEA) scientific guidance for human medicinal products/biologicals guidelines 2008, http://www.emea.europa.eu/htms/human/humanguidelines/biologicals.httm.
3. An introduction to the Indian Pharmaceutical Industry by the Boston analytics 2007, http://www.bostonanalytics.com/leading_thoughts_research/ba_indian_pharmaceutical_market_research_report_10_07.pdf.
4. Indian biogeneric companies on the threshold of globalization. Biospectrum June 2007, 5(6). http://www.biospectrumasia.com/content/130808ind6791.asp.
5. The Mashelkar Committee report on recombinant pharmaceuticals: http://cdsco.nic.in/html/Final%2520Report%2520mashelkar.pdfug.
6. Biotechnological/biological products - central drug standard control organization guidance document for industry: http://cdsco.nic.in/CDSCO-GuidanceForIndustry.pdf.
7. The Indian Pharmacopoeia (IP) 2010, http://ipc.nic.in/writereaddata/linkimages/New%2520Features%2520of%2520IP%252020107592310671.pdf.
8. Shapiro R. Huge potential savings from biogenerics: http://www.thefreelibrary.com/Huge%2Bpotential%2Bsavings%2Bfrom%2Bbiogenerics%253A%2Ba%2Breport%2Bby%2Beconomist%2BDr.-a0199538731.
9. Brockmeyer C. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals. EJHP Practice 2009, 15:24-40.
10. Deechongkit S., Aoki K., Park S., Kerwin B. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci 2006, 95:1931-1943.
11. Mody R., Goradia V., Gupta D. How similar are biosimilars in India? A blind comparative study. Pharma Focus Asia 2009, 11:40-49.